Article
Medicine, General & Internal
Nam Kyeong Kim, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim
Summary: This study aimed to evaluate the effect of therapeutic granulocyte colony-stimulating factor (G-CSF) in preventing recurrence of febrile neutropenia (FN) and survival outcomes in gynecologic cancer patients. The study found that age, previous chemotherapy, thrombocytopenia, and G-CSF dose were associated with FN recurrence. A maximum daily dose of G-CSF ≤ 600 μg was identified as an independent risk factor for recurrent FN.
Article
Oncology
Bernardo Leon Rapoport, Marcial Garcia-Morillo, Carme Font, Zarka Samoon, Adnan Abdul Jabbar, Hampig Raphael Kourie, Aline Kayumba, Francis Esposito, Razvan Andrei Popescu, Jesus Garcia-Gomez, Liezl Heyman, Teresa Smit, Andriy Krendyukov, Nicola Mathieson, Tim Cooksley, Ronald Anderson, Jean Klastersky
Summary: This study aimed to investigate the incidence of febrile neutropenia (FN) in intermediate-risk patients and assess the rationale for using granulocyte colony-stimulating factor (G-CSF) in these patients. The results showed a low incidence of FN in clinical practice, with a decreasing trend in subsequent chemotherapy cycles.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Reshma L. Mahtani, Rajesh Belani, Jeffrey Crawford, David Dale, Lucy DeCosta, Prasad L. Gawade, Chanh Huynh, Tatiana Lawrence, Sandra Lewis, William W. MacLaughlin, Mohit Narang, Robert Rifkin
Summary: This study compared the effectiveness of an on-body injector and other options for preventing FN in breast cancer patients. The results showed that the on-body injector can reduce the incidence of FN, and it also had better adherence.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Mekonnen Dessalegn, Mengistu Fantahun, Abdu Adem Yesufe, Mintewab Hussein, Aster Tsegaye
Summary: A study was conducted at the Oncology unit of St. Paul Hospital Millennium Medical College in Addis Ababa, Ethiopia to assess the incidences of chemotherapy-induced neutropenia and febrile neutropenia in solid cancer patients. The study followed 101 patients diagnosed with any type of solid cancer and found that more than two thirds of the patients experienced chemotherapy-associated neutropenia, while half of the patients had febrile neutropenia. Close monitoring of these patients is necessary.
CANCER MANAGEMENT AND RESEARCH
(2023)
Article
Pediatrics
Federica Cennamo, Riccardo Masetti, Prisca Largo, Alberto Argentiero, Andrea Pession, Susanna Esposito
Summary: Febrile neutropenia is a common complication of chemotherapy in oncological children, emphasizing the importance of early detection and rapid intervention in improving outcomes. Despite efforts to identify specific factors aiding in infection detection and microbiological identification, insufficient evidence exists to establish the role of these risk factors in clinical practice. Further research is needed to develop validated predictive scores and algorithms for the management of febrile neutropenia in pediatric patients.
Article
Oncology
Zi Lin Lim, Peh Joo Ho, Mikael Hartman, Ern Yu Tan, Nur Khaliesah Binte Mohamed Riza, Elaine Hsuen Lim, Phyu Nitar, Jingmei Joint Breast Cancer Registry (JBCR), Fuh Yong Wong, Jingmei Li
Summary: This two-part study found that non-Chinese ethnicity is associated with a higher incidence of febrile neutropenia (FN) in chemotherapy-treated breast cancer patients. Indian patients had a greater decrease in absolute neutrophil count during chemotherapy, while Malay patients were more likely to receive anthracycline treatment, both contributing to higher FN risk. Non-Chinese patients were also more likely to experience multiple FN episodes. Further research is needed to investigate pharmacogenetic differences across ethnicities.
Article
Oncology
Osman Sutcuoglu, Orhun Akdogan, Bediz Kurt Inci, Fatih Gurler, Nuriye ozdemir, Ozan Yazici
Summary: The study aimed to evaluate the impact of uric acid (UA) on 30-day mortality in patients with febrile neutropenia (FEN). Results showed that combining serum UA levels with MASCC risk score could effectively predict 30-day mortality in FEN patients, with a significant increase in mortality rate in patients with high UA levels and MASCC risk scores.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Emergency Medicine
Sejin Heo, Kyeongman Jeon, Boram Park, Ryoung-Eun Ko, Taerim Kim, Sung Yeon Hwang, Hee Yoon, Tae Gun Shin, Won Chul Cha, Se Uk Lee
Summary: This study investigated the characteristics and outcomes of chemotherapy-induced FN patients returning to the ED. It found that shock index, thrombocytopenia, and lactic acid level were associated with an increased risk of a return visit to the ED, while being transferred from other hospitals was associated with a decreased risk.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2023)
Article
Oncology
Hakan Bozcuk, Hasan Senol Coskun, Yusuf Ilhan, Sema Sezgin Goksu, Mustafa Yildiz, Selami Bayram, Tahir Yerlikaya, Murat Kocer, Mehmet Artac, Muzaffer Ugrakli, Ayberk Ouisupov, Alev Aydeniz, Dilhun Sahin, Gozde Yalcin, Meliha Saatci, Hasan Mutlu, Mustafa Yildirim
Summary: The study identifies and quantifies the risk of febrile neutropenia in cancer patients through the development of an algorithm. Internal and external validation tests have shown the accuracy and effectiveness of the algorithm in predicting febrile neutropenia in cancer patients.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Infectious Diseases
Jose C. Alvarez, Sonia I. Cuervo, Edelberto Silva, Jorge A. Diaz, Lorena L. Jimenez, Daniel S. Parra, Julio C. Gomez, Ricardo Sanchez, Jorge A. Cortes
Summary: This study found that continuous infusions of cefepime could effectively achieve PK/PD targets in patients with hematological neoplasms and post-chemotherapy febrile neutropenia.
Article
Microbiology
Maria Bachlitzanaki, George Aletras, Eirini Bachlitzanaki, Ippokratis Messaritakis, Stergos Koukias, Asimina Koulouridi, Emmanouil Bachlitzanakis, Eleni Kaloeidi, Elena Vakonaki, Emmanouil Kontopodis, Nikolaos Androulakis, Georgios Chamilos, Dimitrios Mavroudis, Petros Ioannou, Diamantis Kofteridis
Summary: Febrile neutropenia is a common and serious complication in cancer patients, and this study aimed to investigate the epidemiological and microbiological characteristics of hospitalized patients with solid tumors and neutropenia, as well as factors influencing patient outcomes.
Article
Oncology
Razan Zatarah, Nour Faqeer, Aseel Mahmoud, Tasnim Quraan, Lujain Matalka, Aya Kamal, Lama Nazer
Summary: This study validated the Cycle-Specific Risk of FEbrile Neutropenia after ChEmotherapy ((FENCE)-F-CSR) score for predicting febrile neutropenia. The (FENCE)-F-CSR model can moderately stratify patients into four risk groups for predicting febrile neutropenia prior to chemotherapy cycles 2-6.
Article
Oncology
Kanako Suzuki, Shinsuke Sasada, Hiromi Nishi, Yuri Kimura, Tomoaki Shintani, Akiko Emi, Norio Masumoto, Takayuki Kadoya, Hiroyuki Kawaguchi, Morihito Okada
Summary: Oral hygiene is important in managing oral and febrile complications during chemotherapy for breast cancer. This study found that the incidence of febrile neutropenia (FN) decreased with each treatment cycle and was associated with changes in oral bacteria counts. High oral bacteria count was an independent risk factor for FN development.
Article
Oncology
Yoshitaka Ono, Naoki Hayama, Shigeaki Hattori, Yoko Ito, Tsuyoshi Oguma, Fumio Sakamaki, Koichiro Asano
Summary: This study found that febrile neutropenia (FN) during lung cancer chemotherapy can lead to serious complications and delays or discontinuation of chemotherapy. The Multinational Association of Supportive Care in Cancer (MASCC) and clinical index of stable febrile neutropenia (CISNE) scores are useful in identifying patients who are unable to resume chemotherapy as scheduled after FN.
Article
Multidisciplinary Sciences
Muayad Alali, Anoop Mayampurath, Yangyang Dai, Allison H. Bartlett
Summary: The study aimed to develop a model for predicting blood stream infection (BSI) and transfer to intensive care (TIC) in pediatric cancer patients with febrile neutropenia (FN) using random forest model, which demonstrated higher accuracy.
SCIENTIFIC REPORTS
(2022)